Ellias Helen K. 4
4 · SAB Biotherapeutics, Inc. · Filed Nov 5, 2024
Insider Transaction Report
Form 4
Ellias Helen K.
Director
Transactions
- Award
Stock Option (right to buy)
2024-11-01+20,000→ 20,000 totalExercise: $3.88Exp: 2034-11-01→ Common Stock (20,000 underlying) - Award
Stock Option (right to buy)
2024-11-01+35,000→ 35,000 totalExercise: $3.88Exp: 2034-11-01→ Common Stock (35,000 underlying)
Footnotes (3)
- [F1]Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on November 1, 2025, and 2026.
- [F2]Represents the inaugural grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on November 1, 2025, 2026, and 2027.
- [F3]This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.